Search research articles
Contact Us
Filters
Showing results (71-80 of 81) with videos related to
Page
of 9
Sort By:
British Journal of Cancer
|
August 18, 2011
MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines
E Arriola, I Cañadas, M Arumí-Uría, et al.
Cancer Metastasis Reviews
|
August 1, 2015
New advances in genitourinary cancer: evidence gathered in 2014
C Suárez, J Puente, E Gallardo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 23, 2018
Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
M Gross-Goupil, T G Kwon, M Eto, et al.
BMC Cancer
|
June 5, 2019
First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
A Carrato, M Benavides, B Massutí, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 12, 2015
Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)
E Grande, J Capdevila, D Castellano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial
T Powles, S A Hussain, M A Climent, et al.
BMC Cancer
|
May 25, 2021
Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)
P Grivas, Y Loriot, R Morales-Barrera, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 19, 2017
A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN)
J Bellmunt, J M Kerst, F Vázquez, et al.
ESMO Open
|
April 11, 2022
Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy
E Grande, T Alonso-Gordoa, O Reig, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 5, 2017
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
V Conteduca, D Wetterskog, M T A Sharabiani, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 81) with videos related to
Sort By:
Page
of 9
British Journal of Cancer
|
August 18, 2011
MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines
E Arriola, I Cañadas, M Arumí-Uría, et al.
Cancer Metastasis Reviews
|
August 1, 2015
New advances in genitourinary cancer: evidence gathered in 2014
C Suárez, J Puente, E Gallardo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 23, 2018
Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
M Gross-Goupil, T G Kwon, M Eto, et al.
BMC Cancer
|
June 5, 2019
First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
A Carrato, M Benavides, B Massutí, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 12, 2015
Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)
E Grande, J Capdevila, D Castellano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial
T Powles, S A Hussain, M A Climent, et al.
BMC Cancer
|
May 25, 2021
Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)
P Grivas, Y Loriot, R Morales-Barrera, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 19, 2017
A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN)
J Bellmunt, J M Kerst, F Vázquez, et al.
ESMO Open
|
April 11, 2022
Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy
E Grande, T Alonso-Gordoa, O Reig, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 5, 2017
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
V Conteduca, D Wetterskog, M T A Sharabiani, et al.
Page
of 9